Robert C. Bucelli

Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study

Michael Benatar, Joanne Wuu, Peter M. Andersen et al. · Neurotherapeutics · 2022 · 166 citations · Full text

Life Sciences, Genetics, Neurology +17

Loss- or Gain-of-Function Mutations in ACOX1 Cause Axonal Loss via Different Mechanisms

Hyung-Lok Chung, Michael F. Wangler, Paul C. Marcogliese et al. · Neuron · 2020 · 163 citations · Full text

Life Sciences, Genetics, Neuroscience +8

Chlorpyrifos exerts opposing effects on axonal and dendritic growth in primary neuronal cultures

A HOWARD, Robert C. Bucelli, David A. Jett et al. · Toxicology and Applied Pharmacology · 2005 · 156 citations

Medicine, Neurobiology, Neuroscience +14

TIA1 variant drives myodegeneration in multisystem proteinopathy with SQSTM1 mutations

Youjin Lee, Per Harald Jonson, J. Sarparanta et al. · Journal of Clinical Investigation · 2018 · 109 citations · Full text

Life Sciences, Genetics, Neuroscience +17

Myopathy with anti-HMGCR antibodies

Ali Alshehri, Rati Choksi, Robert C. Bucelli et al. · Neurology Neuroimmunology & Neuroinflammation · 2015 · 108 citations · Full text

Medicine, Immunology, Pathology +17